120711-81-1

Basic information

• Product Name: OTAVA-BB 1217676
• Synonyms: 7-NITRO-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE;OTAVA-BB 1217676;7-Nitro-3,4-dihydro-2H-1,4-benzoxazine;7-Nitro-3,4-dihydro-2H-1,4-benzooxazine;7-Nitro-3,4-dihydro-2H-benzo[1,4]oxazine;7-Nitro-3,4-dihydrobenzo[1,4]oxazine
• CAS NO: 120711-81-1
• Molecular Formula: C₈H₈N₂O₃
• Molecular Weight: 180.162
• Mol File: 120711-81-1.mol
• Article Data: 13

Chemical Properties

• Melting Point: 187-188°
• Boiling Point: 341.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.332±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 0.23±0.20(Predicted)
• Water Solubility: Sparingly soluble in water (0.76 g/L at 25°C).
• CAS DataBase Reference: OTAVA-BB 1217676(CAS DataBase Reference)
• NIST Chemistry Reference: OTAVA-BB 1217676(120711-81-1)
• EPA Substance Registry System: OTAVA-BB 1217676(120711-81-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• HazardClass: IRRITANT
• Hazardous Substances Data: 120711-81-1(Hazardous Substances Data)

Usage

Uses

7-Nitro-3,4-dihydro-2H-1,4-benzooxazine can be used as pain drugs to prevent and treat chronic pain.

Upstream product

• 5466-88-6 3,4-dihydro-3-oxo-2H-1,4-benzoxazine 
• 81721-86-0 7-nitro-4H-benzo[1,4]oxazin-3-one 
• 13292-87-0 dimethyl sulfide borane 
• 120711-94-6 4-acetyl-3,4-dihydro-7-nitro-1,4-benzoxazine 
• 25351-89-7 N-(2-hydroxy-4-nitrophenyl)acetamide 
• 108-24-7 acetic anhydride 
• 5735-53-5 1,4-benzoxazine 
• 106-93-4 ethylene dibromide 
• 121-88-0 5-Nitro-2-aminophenol 
• 99-57-0 2-hydroxy-5-nitroaniline 

Relevant articles and documents

Guanidine compound for preventing and treating chronic pain medication (by machine translation)

The invention relates to a guanidine compound as shown in general formula (I) as a guanidine compound for preventing and treating chronic pain disease. A pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, a deuterated substanc

Quinoline or quinazoline derivatives, its preparation process and its use in medicine

The invention relates to a quinoline or quinazoline derivative, its preparation method and an application in medicines, specifically to new quinoline or quinazoline derivative as shown in a general formula (I) and its medicinal salt or a pharmaceutical composition containing the derivative and a preparation method thereof. The invention further relates to an application of the quinoline or quinazoline derivative and its medicinal salt or the pharmaceutical composition containing the derivative in the preparation of a therapeutic agent, especially a protein kinase inhibitor. Each substituent group in the general formula (I) has the same definition as in the specification.

Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aβ and Aβ plaques in cells and transgenic animals.